Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
Nicole Mittmann, PhD
Advertisement
Articles by Nicole Mittmann, PhD
Advertisement
Latest Updated Articles
- Private-payer Costs for Employees with Treatment-resistant Depression
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Current and Emerging BCMAxCD3 Bispecifics
3
Same Pathway, Different Profiles: Clinical Considerations for Alpelisib, Capivasertib, and Inavolisib
4
Evolocumab Reduces Risk of Major Events in Patients Without Prior Cardiovascular History
5
